Clinical phenotypes and prognosis in patients with venous thromboembolism and cancer: a cluster analysis

Abstract Background Risk stratification in patients with venous thromboembolism (VTE) and cancer is predominantly tumor-centered, although outcomes are also influenced by patient clinical characteristics. Whether clinical phenotyping incorporating patient-level characteristics and cancer activity identifies subgroups with different survival outcomes after accounting for tumor-site thrombotic risk remains insufficiently explored. Methods We conducted a retrospective cohort study of patients with VTE and current or prior malignancy treated at a tertiary referral center in Colombia between January 2011 and January 2025. Clinical phenotypes were identified using multiple correspondence analysis followed by hierarchical clustering (Ward’s method), incorporating cancer activity and patient-level clinical characteristics while excluding primary tumor site and oncologic treatment history. Overall survival (OS) was estimated using Kaplan–Meier analysis. Cox proportional hazards models evaluated the association between clinical phenotypes and mortality, adjusting for tumor-site thrombotic risk classification. Results A total of 654 patients were included (median age 66.6 years; 68.8% female; 72.9% with active cancer at clinic evaluation). Among 620 patients contributing to the time-to-event analyses, median OS was 3.7 years (95% CI 2.8–5.4). Three clinical phenotypes were identified: (1) younger patients with low comorbidity burden ( n = 367) (2), older patients with recent surgical exposure ( n = 211), and (3) older patients with multimorbidity ( n = 76). Median OS differed across phenotypes (2.4, 6.2, and 3.8 years, respectively). Low-molecular-weight heparin was the predominant anticoagulant (76.5%). After adjustment for tumor-site thrombotic risk classification, Cluster 1 was associated with higher mortality compared with Cluster 2 (HR 1.30; 95% CI 1.02–1.65; p = 0.032). Conclusions Among patients with VTE and malignancy, clinical phenotypes incorporating patient-level characteristics and cancer activity were associated with differences in OS. The association between Cluster 1 and higher mortality persisted after adjustment for tumor-site thrombotic risk classification. However, residual confounding by unmeasured determinants of oncologic prognosis cannot be excluded. These findings highlight the clinical heterogeneity of this population and warrant validation using more detailed oncologic information.

Authors

Institutions

Publication Details

Journal
Thrombosis Journal
Published
2026-11-15
DOI
https://doi.org/10.1186/s12959-026-00940-y
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical phenotypes and prognosis in patients with venous thromboembolism and cancer: a cluster analysis

Julián Yara, Jessica Largo, Juan Esteban Gómez‐Mesa, Diana Cristina Carrillo et al.
Thrombosis Journal
Venous Thromboembolism Diagnosis and Management
article

Clinical phenotypes and prognosis in patients with venous thromboembolism and cancer: a cluster analysis

Julián Yara, Jessica Largo, Juan Esteban Gómez‐Mesa, Diana Cristina Carrillo, Arturo D. Mora, Valeria Azcárate-Rodríguez, Frank Cañón-Estrada, David Fernando Narvaez-De Los Rios, Hoover Leon- Giraldo, Manuela Estrada, Mario Miguel Barbosa-Rengifo, Andrés Domínguez-Durán, Juan Pablo Gómez-Arellano, Juan Andres Muñoz
article en

Abstract

Abstract Background Risk stratification in patients with venous thromboembolism (VTE) and cancer is predominantly tumor-centered, although outcomes are also influenced by patient clinical characteristics. Whether clinical phenotyping incorporating patient-level characteristics and cancer activity identifies subgroups with different survival outcomes after accounting for tumor-site thrombotic risk remains insufficiently explored. Methods We conducted a retrospective cohort study of patients with VTE and current or prior malignancy treated at a tertiary referral center in Colombia between January 2011 and January 2025. Clinical phenotypes were identified using multiple correspondence analysis followed by hierarchical clustering (Ward’s method), incorporating cancer activity and patient-level clinical characteristics while excluding primary tumor site and oncologic treatment history. Overall survival (OS) was estimated using Kaplan–Meier analysis. Cox proportional hazards models evaluated the association between clinical phenotypes and mortality, adjusting for tumor-site thrombotic risk classification. Results A total of 654 patients were included (median age 66.6 years; 68.8% female; 72.9% with active cancer at clinic evaluation). Among 620 patients contributing to the time-to-event analyses, median OS was 3.7 years (95% CI 2.8–5.4). Three clinical phenotypes were identified: (1) younger patients with low comorbidity burden ( n = 367) (2), older patients with recent surgical exposure ( n = 211), and (3) older patients with multimorbidity ( n = 76). Median OS differed across phenotypes (2.4, 6.2, and 3.8 years, respectively). Low-molecular-weight heparin was the predominant anticoagulant (76.5%). After adjustment for tumor-site thrombotic risk classification, Cluster 1 was associated with higher mortality compared with Cluster 2 (HR 1.30; 95% CI 1.02–1.65; p = 0.032). Conclusions Among patients with VTE and malignancy, clinical phenotypes incorporating patient-level characteristics and cancer activity were associated with differences in OS. The association between Cluster 1 and higher mortality persisted after adjustment for tumor-site thrombotic risk classification. However, residual confounding by unmeasured determinants of oncologic prognosis cannot be excluded. These findings highlight the clinical heterogeneity of this population and warrant validation using more detailed oncologic information.

Thrombosis Journal
Fundación Valle del Lili (CO), Universidad Icesi (CO)
Fundación Valle del Lili
Good health and well-being
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon